{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:25:15Z","timestamp":1775748315897,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jval.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:57:45Z","timestamp":1722430665000},"page":"1507-1514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch"],"prefix":"10.1016","volume":"27","author":[{"given":"Marina","family":"Richardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Rind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Seidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Emond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2024.07.011_bib3","author":"Tice"},{"issue":"2","key":"10.1016\/j.jval.2024.07.011_bib5","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2024.07.011_bib7","doi-asserted-by":"crossref","unstructured":"2023. American Geriatrics Society beers Criteria\u00ae update expert panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc;71(7):2052-2081.","DOI":"10.1111\/jgs.18372"},{"issue":"34","key":"10.1016\/j.jval.2024.07.011_bib8","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.jval.2024.07.011_bib9","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost-effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jval.2024.07.011_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2024.07.011_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fmed.2020.00107","article-title":"Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis","volume":"7","author":"Deng","year":"2020","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.jval.2024.07.011_bib12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","article-title":"Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation","volume":"132","author":"Graham","year":"2019","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.jval.2024.07.011_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jval.2024.07.011_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40273-023-01302-6","article-title":"An alternative measure of health for value assessment: the equal value life-year","volume":"41","author":"Campbell","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2024.07.011_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between Apixaban, dabigatran, edoxaban, and Rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.jval.2024.07.011_bib18","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of Rivaroxaban vs Apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:55:45Z","timestamp":1762030545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1098301524027943"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}